keyword
MENU ▼
Read by QxMD icon Read
search

Martin S. Tallman

keyword
https://www.readbyqxmd.com/read/27903528/consensus-guidelines-for-the-diagnosis-and-management-of-patients-with-classic-hairy-cell-leukemia
#1
Michael R Grever, Omar Abdel-Wahab, Leslie A Andritsos, Versha Banerji, Jacqueline Barrientos, James S Blachly, Timothy G Call, Daniel Catovsky, Claire Dearden, Judit Demeter, Monica Else, Francesco Forconi, Alessandro Gozzetti, Anthony D Ho, James B Johnston, Jeffrey Jones, Gunnar Juliusson, Eric Kraut, Robert J Kreitman, Loree Larratt, Francesco Lauria, Gerard Lozanski, Emili Montserrat, Sameer A Parikh, Jae H Park, Aaron Polliack, Graeme R Quest, Kanti R Rai, Farhad Ravandi, Tadeusz Robak, Alan Saven, John F Seymour, Tamar Tadmor, Martin S Tallman, Constantine Tam, Enrico Tiacci, Xavier Troussard, Clive S Zent, Thorsten Zenz, Pier Luigi Zinzani, Brunangelo Falini
Hairy cell leukemia is an uncommon hematologic malignancy characterized by pancytopenia and marked susceptibility to infection. Tremendous progress in the management of patients with this disease has resulted in high response rates and improved survival, yet relapse and an appropriate approach to re-treatment present continuing areas for research. The disease and its effective treatment are associated with immunosuppression. As more patients are being treated with alternative programs, comparison of results will require general agreement on definitions of response, relapse, and methods of determining minimal residual disease...
November 30, 2016: Blood
https://www.readbyqxmd.com/read/27895058/diagnosis-and-management-of-aml-in-adults-2017-eln-recommendations-from-an-international-expert-panel
#2
Hartmut Döhner, Elihu Estey, David Grimwade, Sergio Amadori, Frederick R Appelbaum, Thomas Büchner, Hervé Dombret, Benjamin L Ebert, Pierre Fenaux, Richard A Larson, Ross L Levine, Francesco Lo-Coco, Tomoki Naoe, Dietger Niederwieser, Gert J Ossenkoppele, Miguel Sanz, Jorge Sierra, Martin S Tallman, Hwei-Fang Tien, Andrew H Wei, Bob Löwenberg, Clara D Bloomfield
The first edition of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults published in 2010 has found broad acceptance by physicians and investigators caring for patients with AML. Recent advances, for example, in the discovery of the genomic landscape of the disease, in the development of assays for genetic testing and for detecting minimal residual disease, as well as in the development of novel anti-leukemic agents, prompted an international panel to provide updated evidence- and expert opinion-based recommendations...
November 28, 2016: Blood
https://www.readbyqxmd.com/read/27870571/high-frequency-and-poor-outcome-of-philadelphia-chromosome-like-acute-lymphoblastic-leukemia-in-adults
#3
Kathryn G Roberts, Zhaohui Gu, Debbie Payne-Turner, Kelly McCastlain, Richard C Harvey, I-Ming Chen, Deqing Pei, Ilaria Iacobucci, Marcus Valentine, Stanley B Pounds, Lei Shi, Yongjin Li, Jinghui Zhang, Cheng Cheng, Alessandro Rambaldi, Manuela Tosi, Orietta Spinelli, Jerald P Radich, Mark D Minden, Jacob M Rowe, Selina Luger, Mark R Litzow, Martin S Tallman, Peter H Wiernik, Ravi Bhatia, Ibrahim Aldoss, Jessica Kohlschmidt, Krzysztof Mrózek, Guido Marcucci, Clara D Bloomfield, Wendy Stock, Stephen Kornblau, Hagop M Kantarjian, Marina Konopleva, Elisabeth Paietta, Cheryl L Willman, Charles G Mullighan
Purpose Philadelphia chromosome (Ph) -like acute lymphoblastic leukemia (ALL) is a high-risk subtype of childhood ALL characterized by kinase-activating alterations that are amenable to treatment with tyrosine kinase inhibitors. We sought to define the prevalence and genomic landscape of Ph-like ALL in adults and assess response to conventional chemotherapy. Patients and Methods The frequency of Ph-like ALL was assessed by gene expression profiling of 798 patients with B-cell ALL age 21 to 86 years. Event-free survival and overall survival were determined for Ph-like ALL versus non-Ph-like ALL patients...
November 21, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27811189/down-for-the-count-in-acute-myeloid-leukemia
#4
Aaron D Goldberg, Martin S Tallman
No abstract text is available yet for this article.
November 3, 2016: Blood
https://www.readbyqxmd.com/read/27776115/deregulation-of-dux4-and-erg-in-acute-lymphoblastic-leukemia
#5
Jinghui Zhang, Kelly McCastlain, Hiroki Yoshihara, Beisi Xu, Yunchao Chang, Michelle L Churchman, Gang Wu, Yongjin Li, Lei Wei, Ilaria Iacobucci, Yu Liu, Chunxu Qu, Ji Wen, Michael Edmonson, Debbie Payne-Turner, Kerstin B Kaufmann, Shin-Ichiro Takayanagi, Erno Wienholds, Esmé Waanders, Panagiotis Ntziachristos, Sofia Bakogianni, Jingjing Wang, Iannis Aifantis, Kathryn G Roberts, Jing Ma, Guangchun Song, John Easton, Heather L Mulder, Xiang Chen, Scott Newman, Xiaotu Ma, Michael Rusch, Pankaj Gupta, Kristy Boggs, Bhavin Vadodaria, James Dalton, Yanling Liu, Marcus L Valentine, Li Ding, Charles Lu, Robert S Fulton, Lucinda Fulton, Yashodhan Tabib, Kerri Ochoa, Meenakshi Devidas, Deqing Pei, Cheng Cheng, Jun Yang, William E Evans, Mary V Relling, Ching-Hon Pui, Sima Jeha, Richard C Harvey, I-Ming L Chen, Cheryl L Willman, Guido Marcucci, Clara D Bloomfield, Jessica Kohlschmidt, Krzysztof Mrózek, Elisabeth Paietta, Martin S Tallman, Wendy Stock, Matthew C Foster, Janis Racevskis, Jacob M Rowe, Selina Luger, Steven M Kornblau, Sheila A Shurtleff, Susana C Raimondi, Elaine R Mardis, Richard K Wilson, John E Dick, Stephen P Hunger, Mignon L Loh, James R Downing, Charles G Mullighan
Chromosomal rearrangements deregulating hematopoietic transcription factors are common in acute lymphoblastic leukemia (ALL). Here we show that deregulation of the homeobox transcription factor gene DUX4 and the ETS transcription factor gene ERG is a hallmark of a subtype of B-progenitor ALL that comprises up to 7% of B-ALL. DUX4 rearrangement and overexpression was present in all cases and was accompanied by transcriptional deregulation of ERG, expression of a novel ERG isoform, ERGalt, and frequent ERG deletion...
October 24, 2016: Nature Genetics
https://www.readbyqxmd.com/read/27734609/a-phase-1-study-of-intravenous-infusions-of-tigecycline-in-patients-with-acute-myeloid-leukemia
#6
Gregory A Reed, Gary J Schiller, Suman Kambhampati, Martin S Tallman, Dan Douer, Mark D Minden, Karen W Yee, Vikas Gupta, Joseph Brandwein, Yulia Jitkova, Marcela Gronda, Rose Hurren, Aisha Shamas-Din, Andre C Schuh, Aaron D Schimmer
Acute myeloid leukemia (AML) cells meet the higher energy, metabolic, and signaling demands of the cell by increasing mitochondrial biogenesis and mitochondrial protein translation. Blocking mitochondrial protein synthesis through genetic and chemical approaches kills human AML cells at all stages of development in vitro and in vivo. Tigecycline is an antimicrobial that we found inhibits mitochondrial protein synthesis in AML cells. Therefore, we conducted a phase 1 dose-escalation study of tigecycline administered intravenously daily 5 of 7 days for 2 weeks to patients with AML...
November 2016: Cancer Medicine
https://www.readbyqxmd.com/read/27632567/telomere-length-recovery-a-strong-predictor-of-overall-survival-in-acute-promyelocytic-leukemia
#7
Muhamed Baljevic, Bogdan Dumitriu, Ju-Whei Lee, Elisabeth M Paietta, Peter H Wiernik, Janis Racevskis, Christina Chen, Eytan M Stein, Robert E Gallagher, Jacob M Rowe, Frederick R Appelbaum, Bayard L Powell, Richard A Larson, Steven E Coutré, Jeffrey Lancet, Mark R Litzow, Selina M Luger, Neal S Young, Martin S Tallman
Telomeres are the capping ends of chromosomes that protect the loss of genetic material and prevent chromosomal instability. In human tissue-specific stem/progenitor cells, telomere length (TL) is maintained by the telomerase complex, which consists of a reverse transcriptase catalytic subunit (TERT) and an RNA template (TERC). Very short telomeres and loss-of-function mutations in the TERT and TERC genes have been reported in acute myeloid leukemia, but the role of telomeres in acute promyelocytic leukemia (APL) has not been well established...
2016: Acta Haematologica
https://www.readbyqxmd.com/read/27631159/the-use-of-erwinia-asparaginase-for-adult-patients-with-acute-lymphoblastic-leukemia-after-pegaspargase-intolerance
#8
Troy Z Horvat, Joshua J Pecoraro, Ryan J Daley, Larry W Buie, Amber C King, Raajit K Rampal, Martin S Tallman, Jae H Park, Dan Douer
Asparaginase administration has become a crucial component of front-line pediatric and pediatric-insipired multi-agent regimens for the treatment of acute lymphoblastic leukemia (ALL). The aim of this retrospective study was to assess the safety and feasibility of switching to Erwinia asparaginase after pegaspargase intolerance in adult ALL patients treated at Memorial Sloan Kettering Cancer Center. Our analysis included 10 patients, with a median age of 39 years (range 20-72), male predominance (90%), and a typical B-cell to T-cell ratio (70:30%) for ALL...
August 26, 2016: Leukemia Research
https://www.readbyqxmd.com/read/27573652/extramedullary-disease-in-adult-acute-myeloid-leukemia-is-common-but-lacks-independent-significance-analysis-of-patients-in-ecog-acrin-cancer-research-group-trials-1980-2008
#9
Chezi Ganzel, Judith Manola, Dan Douer, Jacob M Rowe, Hugo F Fernandez, Elisabeth M Paietta, Mark R Litzow, Ju-Whei Lee, Selina M Luger, Hillard M Lazarus, Larry D Cripe, Martin S Tallman
PURPOSE: Extramedullary disease (EMD) at diagnosis in patients with acute myeloid leukemia (AML) has been recognized for decades. Reported herein are results from a large study of patients with AML who were treated in consecutive ECOG-ACRIN Cancer Research Group frontline clinical trials in an attempt to define the incidence and clinical implications of EMD. METHODS: Patients with newly diagnosed AML, age 15 years and older, who were treated in 11 clinical trials, were studied to identify EMD, as defined by physical examination, laboratory findings, and imaging results...
August 29, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27568819/telomere-length-and-associations-with-somatic-mutations-and-clinical-outcomes-in-acute-myeloid-leukemia
#10
Justin M Watts, Bogdan Dumitriu, Patrick Hilden, Ashwin Kishtagari, Franck Rapaport, Christina Chen, Jihae Ahn, Sean M Devlin, Eytan M Stein, Raajit Rampal, Ross L Levine, Neal Young, Martin S Tallman
We examined the genetic implications and clinical impact of telomere length (TL) in 67 patients with acute myeloid leukemia (AML). There was a trend toward improved survival at 6 months in patients with longer TL. We found that patients with activating mutations, such as FLT3-ITD, had shorter TL, while those with mutations in epigenetic modifying enzymes, particularly IDH1 and IDH2, had longer TL. These are intriguing findings that warrant further investigation in larger cohorts. Our data show the potential of TL as a predictive biomarker in AML and identify genetic subsets that may be particularly vulnerable to telomere-targeted therapies...
October 2016: Leukemia Research
https://www.readbyqxmd.com/read/27468137/delays-in-postremission-chemotherapy-for-philadelphia-chromosome-negative-acute-lymphoblastic-leukemia-are-associated-with-inferior-outcomes-in-patients-who-undergo-allogeneic-transplant-an-analysis-from-ecog-2993-mrc-uk-allxii
#11
Anita J Kumar, Phyllis A Gimotty, Joel Gelfand, Georgina Buck, Jacob M Rowe, Anthony H Goldstone, Adele Fielding, David I Marks, Mark Litzow, Elisabeth Paietta, Hillard M Lazarus, Martin S Tallman, Selina M Luger, Alison W Loren
Adults with acute lymphoblastic leukemia (ALL) have a poorer prognosis than children due to a high risk of relapse. One explanation may be variable adherence to dose-intense chemotherapy. However, little is known about risk factors for delays in therapy and their impact on survival. We conducted an analysis of ECOG 2993/UKALLXII trial to study delays in postremission chemotherapy in adults with newly diagnosed ALL. Logistic regression was used to identify risk factors for a very long delay (VLD, >4 weeks) in start of intensification therapy...
November 2016: American Journal of Hematology
https://www.readbyqxmd.com/read/27446991/a-clinical-measure-of-dna-methylation-predicts-outcome-in-de-novo-acute-myeloid-leukemia
#12
Marlise R Luskin, Phyllis A Gimotty, Catherine Smith, Alison W Loren, Maria E Figueroa, Jenna Harrison, Zhuoxin Sun, Martin S Tallman, Elisabeth M Paietta, Mark R Litzow, Ari M Melnick, Ross L Levine, Hugo F Fernandez, Selina M Luger, Martin Carroll, Stephen R Master, Gerald B W Wertheim
BACKGROUND: Variable response to chemotherapy in acute myeloid leukemia (AML) represents a major treatment challenge. Clinical and genetic features incompletely predict outcome. The value of clinical epigenetic assays for risk classification has not been extensively explored. We assess the prognostic implications of a clinical assay for multilocus DNA methylation on adult patients with de novo AML. METHODS: We performed multilocus DNA methylation assessment using xMELP on samples and calculated a methylation statistic (M-score) for 166 patients from UPENN with de novo AML who received induction chemotherapy...
June 16, 2016: JCI Insight
https://www.readbyqxmd.com/read/27418649/mutational-correlates-of-response-to-hypomethylating-agent-therapy-in-acute-myeloid-leukemia
#13
LETTER
Catherine C Coombs, David A Sallman, Sean M Devlin, Shweta Dixit, Abhinita Mohanty, Kristina Knapp, Najla H Al Ali, Jeffrey E Lancet, Alan F List, Rami S Komrokji, Eric Padron, Maria E Arcila, Virginia M Klimek, Marcel R M van den Brink, Martin S Tallman, Ross L Levine, Raajit K Rampal, Franck Rapaport
No abstract text is available yet for this article.
November 2016: Haematologica
https://www.readbyqxmd.com/read/27363283/patient-derived-xenotransplants-can-recapitulate-the-genetic-driver-landscape-of-acute-leukemias
#14
K Wang, M Sanchez-Martin, X Wang, K M Knapp, R Koche, L Vu, M K Nahas, J He, M Hadler, E M Stein, M S Tallman, A L Donahue, G M Frampton, D Lipson, S Roels, P J Stephens, E M Sanford, T Brennan, G A Otto, R Yelensky, V A Miller, M G Kharas, R L Levine, A Ferrando, S A Armstrong, A V Krivtsov
Genomic studies have identified recurrent somatic mutations in acute leukemias. However, current murine models do not sufficiently encompass the genomic complexity of human leukemias. To develop preclinical models, we transplanted 160 samples from patients with acute leukemia (acute myeloid leukemia, mixed lineage leukemia, B-cell acute lymphoblastic leukemia, T-cell ALL) into immunodeficient mice. Of these, 119 engrafted with expected immunophenotype. Targeted sequencing of 374 genes and 265 frequently rearranged RNAs detected recurrent and novel genetic lesions in 48 paired primary tumor (PT) and patient-derived xenotransplant (PDX) samples...
July 1, 2016: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/27354720/maintenance-therapy-in-acute-myeloid-leukemia-an-evidence-based-review-of-randomized-trials
#15
REVIEW
Armin Rashidi, Roland B Walter, Martin S Tallman, Frederick R Appelbaum, John F DiPersio
No abstract text is available yet for this article.
August 11, 2016: Blood
https://www.readbyqxmd.com/read/27351754/treatment-outcomes-and-secondary-cancer-incidence-in-young-patients-with-hairy-cell-leukaemia
#16
Bartlomiej M Getta, Kaitlin M Woo, Sean Devlin, Jae H Park, Omar Abdel-Wahab, Alan Saven, Kanti Rai, Martin S Tallman
Repeated therapy of hairy cell leukaemia (HCL) with treatments that have potential long-term toxicities has raised concerns regarding increased risk for younger patients. We compared clinical outcomes and disease complications in 63 patients with HCL aged ≤40 years at diagnosis with 268 patients >40 years treated at Memorial Sloan Kettering Cancer Center. The rate of complete remission following initial therapy was 87% and 83% (P = 0·71) and estimated 10-year overall survival was 100% and 82% (P = 0·25) in younger and older patients, respectively...
November 2016: British Journal of Haematology
https://www.readbyqxmd.com/read/27235136/how-i-treat-acute-myeloid-leukemia-presenting-with-preexisting-comorbidities
#17
Yishai Ofran, Martin S Tallman, Jacob M Rowe
Acute myeloid leukemia (AML) is a devastating disease with an incidence that progressively increases with advancing age. Currently, only ∼40% of younger and 10% of older adults are long-term survivors. If untreated, the overall prognosis of AML remains dismal. Initiation of therapy at diagnosis is usually urgent. Barriers to successful therapy for AML are the attendant toxicities directly related to chemotherapy or those associated with inevitable aplasia. Organ dysfunction often further complicates such toxicities and may even be prohibitive...
July 28, 2016: Blood
https://www.readbyqxmd.com/read/27088965/association-between-anticholinergic-medication-use-and-cognition-brain-metabolism-and-brain-atrophy-in-cognitively-normal-older-adults
#18
Shannon L Risacher, Brenna C McDonald, Eileen F Tallman, John D West, Martin R Farlow, Fredrick W Unverzagt, Sujuan Gao, Malaz Boustani, Paul K Crane, Ronald C Petersen, Clifford R Jack, William J Jagust, Paul S Aisen, Michael W Weiner, Andrew J Saykin
IMPORTANCE: The use of anticholinergic (AC) medication is linked to cognitive impairment and an increased risk of dementia. To our knowledge, this is the first study to investigate the association between AC medication use and neuroimaging biomarkers of brain metabolism and atrophy as a proxy for understanding the underlying biology of the clinical effects of AC medications. OBJECTIVE: To assess the association between AC medication use and cognition, glucose metabolism, and brain atrophy in cognitively normal older adults from the Alzheimer's Disease Neuroimaging Initiative (ADNI) and the Indiana Memory and Aging Study (IMAS)...
June 1, 2016: JAMA Neurology
https://www.readbyqxmd.com/read/27016502/dnmt3a-haploinsufficiency-transforms-flt3itd-myeloproliferative-disease-into-a-rapid-spontaneous-and-fully-penetrant-acute-myeloid-leukemia
#19
Sara E Meyer, Tingting Qin, David E Muench, Kohei Masuda, Meenakshi Venkatasubramanian, Emily Orr, Lauren Suarez, Steven D Gore, Ruud Delwel, Elisabeth Paietta, Martin S Tallman, Hugo Fernandez, Ari Melnick, Michelle M Le Beau, Scott Kogan, Nathan Salomonis, Maria E Figueroa, H Leighton Grimes
UNLABELLED: Cytogenetically normal acute myeloid leukemia (CN-AML) represents nearly 50% of human AML. Co-occurring mutations in the de novo DNA methyltransferase DNMT3A and the FMS related tyrosine kinase 3 (FLT3) are common in CN-AML and confer a poorer prognosis. We demonstrate that mice with Flt3-internal tandem duplication (Flt3(ITD)) and inducible deletion of Dnmt3a spontaneously develop a rapidly lethal, completely penetrant, and transplantable AML of normal karyotype. AML cells retain a single Dnmt3a floxed allele, revealing the oncogenic potential of Dnmt3a haploinsufficiency...
May 2016: Cancer Discovery
https://www.readbyqxmd.com/read/26859458/truncating-erythropoietin-receptor-rearrangements-in-acute-lymphoblastic-leukemia
#20
Ilaria Iacobucci, Yongjin Li, Kathryn G Roberts, Stephanie M Dobson, Jaeseung C Kim, Debbie Payne-Turner, Richard C Harvey, Marcus Valentine, Kelly McCastlain, John Easton, Donald Yergeau, Laura J Janke, Ying Shao, I-Ming L Chen, Michael Rusch, Sasan Zandi, Steven M Kornblau, Marina Konopleva, Elias Jabbour, Elisabeth M Paietta, Jacob M Rowe, Ching-Hon Pui, Julie Gastier-Foster, Zhaohui Gu, Shalini Reshmi, Mignon L Loh, Janis Racevskis, Martin S Tallman, Peter H Wiernik, Mark R Litzow, Cheryl L Willman, John D McPherson, James R Downing, Jinghui Zhang, John E Dick, Stephen P Hunger, Charles G Mullighan
Chromosomal rearrangements are a hallmark of acute lymphoblastic leukemia (ALL) and are important ALL initiating events. We describe four different rearrangements of the erythropoietin receptor gene EPOR in Philadelphia chromosome-like (Ph-like) ALL. All of these rearrangements result in truncation of the cytoplasmic tail of EPOR at residues similar to those mutated in primary familial congenital polycythemia, with preservation of the proximal tyrosine essential for receptor activation and loss of distal regulatory residues...
February 8, 2016: Cancer Cell
keyword
keyword
114531
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"